Acasti Pharma Inc ACST

Healthcare

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

NDAQ:ACST - Post by User

Acasti Pharma Inc > Dow Jones index

<< Previous

Bullboard Posts

Next >>

Comment by EternalPonzion Mar 22, 2020 10:29pm

87 Views

Post# 30836199

RE:RE:Dow Jones index

The only guarantee is the US dollar will no longer be the reserve currency much sooner than anyone could imagine. The US will fight hard but their wishes will be ignored and irrelevant. There will never again be a shortage of toilet paper as any square no one can spare will easily be replaced with a George Washington. Things are going to get very grim.

<< Previous

Bullboard Posts

Next >>

2024, a breakthrough year for silver